Q
Q/C TECHNOLOGIES, INC.
QCLSCIK 0001321834NasdaqNon-AcceleratedSmaller ReportingIn Vitro & In Vivo Diagnostic SubstancesDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-11.63M
Total Assets
—
Equity
—
Shares Out
7.85M
Op. Cash Flow
$-9.07M
Business
Q/C Technologies, Inc. develops laser-based computing systems for blockchain, artificial intelligence, and high-performance computing through an exclusive global licensing agreement with LightSolver Ltd. The company's primary product is the qc-LPU100, a quantum-class laser processing unit designed to solve complex computational problems with improved energy efficiency. The company also maintains a legacy pharmaceutical business with clinical-stage therapeutic candidates. It targets cryptocurrency infrastructure and AI-driven computing environments.
Summary from 10-K filed 2026-04-15
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Product Revenue | — | — | — | — | — | |
| Product Cost of Sales | — | — | — | — | — | |
| Gross Income | — | — | — | — | — | |
| Administrative Expenses | 4 | 4 | 5 | 6 | 6 | |
| Research and Development Expenses | 3 | 3 | 8 | 9 | 7 | |
| Stock Based Compensation | 2 | 1 | 3 | 695,191 | — | |
| Franchise Tax Expense | 200,050 | — | — | — | — | |
| Series F-1 Warrant Issuance Expenses | — | 539,097 | — | — | — | |
| Series G Warrant Issuance Expenses | — | 969,505 | — | — | — | |
| Series H Warrant Issuance Expenses | 264,417 | — | — | — | — | |
| Loss from Operations | −10 | −10 | −17 | −15 | −29 | |
| Interest and Dividend Income | −225,388 | −351,809 | −455,570 | −83,991 | −8,907 | |
| Gain on Sales of Marketable Securities | −2,176 | −976 | −416 | — | — | |
| Unrealized Gain on Marketable Securities | −38,671 | −671 | −514 | −2,958 | 42,793 | |
| Impairment on Equity Investment | 2 | — | — | — | — | |
| Change in fair value of Derivatives Liabilities | −983,000 | 388,000 | −3 | — | — | |
| Change in fair value of Contingent Consideration | 2 | — | — | — | — | |
| Change in fair value of Warrant Liabilities | — | 4 | −10 | — | — | |
| Loss on issuance of Series F-1 Convertible Preferred Stock | — | 4 | — | — | — | |
| Loss on issuance of Series G Convertible Preferred Stock | — | 5 | — | — | — | |
| Casualty Loss/(Gain) | — | −100,000 | 178,198 | −4,442 | — | |
| Total Other (Income) Expenses | 2 | 13 | −13 | −85,427 | 1 | |
| Loss Before Income Taxes | −12 | −23 | −4 | −15 | −30 | |
| Income Taxes | — | — | — | — | — | |
| Net Loss | −12 | −23 | −4 | −15 | −30 | |
| Preferred Stock Dividends | 3 | 4 | 4 | — | — | |
| Net Loss Attributable to Common Stockholders | −15 | −27 | −8 | −15 | — | |
| Basic net loss per common share | −8.66 | −1,081 | −5.33 | −11.74 | −0.85 | |
| Diluted net loss per common share | −8.66 | −1,081 | −5.33 | −11.74 | — | |
| Weighted average basic common stock outstanding | 2 | 25,129 | 2 | 1 | 35 | |
| Weighted average diluted common stock outstanding | 2 | 25,129 | 2 | 1 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | 986,996 | 173,154 | 3 | 749,090 | 555,967 | |
| Marketable Securities | 15 | 8 | 2 | 4 | 11 | |
| Deposits and Other Receivables | 18,200 | — | — | — | — | |
| Prepaid Expenses | 774,095 | 893,730 | 893,226 | 565,787 | 1 | |
| Total Current Assets | 17 | 9 | 6 | 5 | 13 | |
| Operating Lease Right-of-Use Assets | — | 10,579 | 47,389 | 139,662 | 149,009 | |
| Intangible Assets | 14 | — | — | — | — | |
| Goodwill | 10 | 10 | 10 | 10 | 10 | |
| Investment in Oravax, Inc. | — | 2 | 2 | — | — | |
| Total Non-Current Assets | 25 | 12 | 12 | 12 | 12 | |
| Total Assets | 41 | 21 | 18 | 18 | 25 | |
| Trade and Other Payables | 2 | 3 | 4 | 3 | 986,626 | |
| Due to MyMD Florida Shareholders | 29,982 | 29,982 | — | — | — | |
| Operating Lease Liability | — | 10,579 | 48,870 | 65,780 | 53,240 | |
| Derivative Liabilities | 2 | 1 | 61,000 | — | — | |
| Dividends Payable | 365,970 | 2 | 265,019 | — | — | |
| License Fee Payable | 533,744 | — | — | — | — | |
| Total Current Liabilities | 6 | 7 | 5 | 3 | 1 | |
| Contingent Consideration Payable | 11 | — | — | — | — | |
| Total Non-Current Liabilities | 11 | — | 100,538 | 75,941 | 125,893 | |
| Total Liabilities | 16 | 7 | 5 | 3 | 1 | |
| Commitments and Contingencies Note 8 | — | — | — | — | — | |
| Total Mezzanine Equity | 3 | 5 | — | — | — | |
| Common Stock, par value $0.001, 1,250,000,000 shares authorized 7,690,403 and 33,636 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 184,502 | 3,364 | 2,019 | 1,316 | 102 | |
| Additional Paid in Capital | 166 | 139 | 114 | 108 | — | |
| Accumulated Deficit | −144 | −129 | −102 | −94 | −79 | |
| Total Stockholders Equity | 22 | 10 | 12 | 15 | 24 | |
| Total Liabilities and Stockholders Equity | 41 | 21 | 18 | 18 | 25 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Gain on sale of marketable securities | −2,176 | −976 | −416 | — | — | |
| Change in fair value of marketable securities | −38,671 | −671 | — | — | — | |
| Change in fair value of derivatives | −983,000 | 388,000 | −3 | — | — | |
| Impairment of intangible assets | 2 | — | — | — | — | |
| Options/RSUs issued to directors | 1 | 476,563 | 944,834 | — | — | |
| Options/RSUs issued to key employees | 104,506 | 507,390 | 2 | 338,922 | — | |
| Options/RSUs issued to non-employees | 777,069 | 73,318 | 142,565 | 105,420 | 90,002 | |
| Shares issued for services | 72,341 | 600,000 | — | 84,851 | — | |
| Accounts receivables | −18,200 | — | — | — | — | |
| Prepaid expenses | 119,635 | −504 | −327,439 | 540,560 | −912,815 | |
| Trade and other payables | −881,382 | −814,114 | 1 | 2 | −4 | |
| License fees payable | −838,227 | — | — | — | — | |
| Operating leases | — | −1,481 | −578 | 1,917 | −81 | |
| Deferred compensation payable | — | −100,538 | 100,538 | — | — | |
| Net cash used in operating activities | −9 | −9 | −13 | −12 | −20 | |
| Purchase of technology license | −2 | — | — | — | — | |
| Purchases of marketable securities | −19 | −13 | −13 | −5 | −13,403 | |
| Proceeds from sale of marketable securities | 13 | 7 | 15 | 12 | 18 | |
| Net cash (used in investing activities | −8 | −6 | 2 | 7 | 20 | |
| Net proceeds from the issuance of Series F Convertible Preferred Stock | — | — | 15 | — | — | |
| Net proceeds from the issuance of Series F-1 Convertible Preferred Stock | — | 5 | 15 | — | — | |
| Net proceeds from the issuance of Series G Convertible Preferred Stock | — | 9 | — | — | — | |
| Net proceeds from the issuance of Series H Convertible Preferred Stock | 7 | — | — | — | — | |
| Net proceeds from the exercise of warrants for common stock | 12 | — | — | — | — | |
| Redemption of Convertible Preferred Stock | — | −73,472 | −89,635 | — | — | |
| Dividend on Convertible Preferred Stock | −77,626 | −1 | −1 | — | — | |
| Premium on Convertible Preferred Stock | — | — | −77,090 | — | — | |
| Net cash provided by financing activities | 18 | 13 | 13 | 6 | 73,533 | |
| Net increase/(decrease) in cash and cash equivalents | 813,842 | −3 | 2 | 193,123 | 407,683 | |
| Interest | — | — | — | 13,322 | 271,800 | |
| Income Taxes | — | — | — | — | — | |
| Fair value of Series G Convertible Preferred Stock issued in-lieu of dividends | 2 | — | — | — | — | |
| Initial fair value of derivative liabilities pursuant to the issuance of Series H Convertible Preferred Stock and Warrants | 2 | — | — | — | — | |
| Contingent Consideration Payable for the issuance of Series I Convertible Preferred Stock | 9 | — | — | — | — | |
| Initial fair value of the LightSolver technology license | 12 | — | — | — | — | |
| Initial fair value of warrant liabilities pursuant to the issuance of Series F-1 Convertible Preferred Stock and Warrants | — | 8 | — | — | — | |
| Initial fair value of derivative liabilities pursuant to the issuance of Series F-1 Convertible Preferred Stock and Warrants | — | 854,000 | — | — | — | |
| Initial fair value of warrant liabilities pursuant to the issuance of Series G Convertible Preferred Stock and Warrants | — | 14 | — | — | — | |
| Reclass of warrant liability to equity upon warrant modification for the Series F Warrants | — | 8 | — | — | — | |
| Reclass of warrant liability to equity upon warrant modification for the Series F-1 Warrants | — | 7 | — | — | — | |
| Reclass of warrant liability to equity upon warrant modification for the Series G Warrants | — | 12 | — | — | — | |
| Modification of Series F Convertible Preferred Stock | — | 5 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Q/C TECHNOLOGIES, INC.'s CIK number?
Q/C TECHNOLOGIES, INC.'s SEC CIK number is 0001321834 (1321834). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Q/C TECHNOLOGIES, INC.'s SEC filings?
All of Q/C TECHNOLOGIES, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.